JP4860606B2 - 糖尿病の処置にｇｌｋアクチベーターとして用いるためのヘテロアリールベンズアミド誘導体 - Google Patents
糖尿病の処置にｇｌｋアクチベーターとして用いるためのヘテロアリールベンズアミド誘導体 Download PDFInfo
- Publication number
- JP4860606B2 JP4860606B2 JP2007514127A JP2007514127A JP4860606B2 JP 4860606 B2 JP4860606 B2 JP 4860606B2 JP 2007514127 A JP2007514127 A JP 2007514127A JP 2007514127 A JP2007514127 A JP 2007514127A JP 4860606 B2 JP4860606 B2 JP 4860606B2
- Authority
- JP
- Japan
- Prior art keywords
- hydroxy
- methyl
- benzamide
- methylethoxy
- het
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- GJDCNROAKOCYIQ-UHFFFAOYSA-N CC(C)(C)OC([n](c(C)c1)nc1N)=O Chemical compound CC(C)(C)OC([n](c(C)c1)nc1N)=O GJDCNROAKOCYIQ-UHFFFAOYSA-N 0.000 description 1
- PILBKGWUYHBUGS-DEOSSOPVSA-N CC(C)[Si](C(C)C)(C(C)C)OC[C@H](C)Oc1cc(C(Nc2n[n](C)cc2)=O)cc(OCc2ccccc2)c1 Chemical compound CC(C)[Si](C(C)C)(C(C)C)OC[C@H](C)Oc1cc(C(Nc2n[n](C)cc2)=O)cc(OCc2ccccc2)c1 PILBKGWUYHBUGS-DEOSSOPVSA-N 0.000 description 1
- DDPIXQLSJXBHGF-UHFFFAOYSA-N COC(c1cc(O)cc(OCc2ccccc2)c1)=O Chemical compound COC(c1cc(O)cc(OCc2ccccc2)c1)=O DDPIXQLSJXBHGF-UHFFFAOYSA-N 0.000 description 1
- FJGSJVPZWAFEEK-FWWRYZNZSA-O C[C@@H](CO)Oc1cc(C(NC(/C=C\NC)=[NH2+])=O)cc(Oc(cc2)cc(F)c2OC)c1 Chemical compound C[C@@H](CO)Oc1cc(C(NC(/C=C\NC)=[NH2+])=O)cc(Oc(cc2)cc(F)c2OC)c1 FJGSJVPZWAFEEK-FWWRYZNZSA-O 0.000 description 1
- IHDUYWKRFWZPTQ-JTQLQIEISA-N C[C@@H](CO)Oc1cc(C(Nc2cnc(C)cn2)=O)cc(O)c1 Chemical compound C[C@@H](CO)Oc1cc(C(Nc2cnc(C)cn2)=O)cc(O)c1 IHDUYWKRFWZPTQ-JTQLQIEISA-N 0.000 description 1
- ZJWOGKQAEOAHBB-KRWDZBQOSA-N C[C@@H](CO)Oc1cc(C(Nc2cnc(C)cn2)=O)cc(Oc(cc2)ccc2C(N2CCC2)=O)c1 Chemical compound C[C@@H](CO)Oc1cc(C(Nc2cnc(C)cn2)=O)cc(Oc(cc2)ccc2C(N2CCC2)=O)c1 ZJWOGKQAEOAHBB-KRWDZBQOSA-N 0.000 description 1
- HUEGYHYYJDUQKQ-ZETCQYMHSA-N C[C@@H](CO)Oc1cc(C(OC)=O)cc(O)c1 Chemical compound C[C@@H](CO)Oc1cc(C(OC)=O)cc(O)c1 HUEGYHYYJDUQKQ-ZETCQYMHSA-N 0.000 description 1
- VWOLVFIHSACTHR-SFHVURJKSA-N C[C@@H](CO[Si+](C)(C)C(C)(C)C)Oc1cc(C(OC)=O)cc(OCc2ccccc2)c1 Chemical compound C[C@@H](CO[Si+](C)(C)C(C)(C)C)Oc1cc(C(OC)=O)cc(OCc2ccccc2)c1 VWOLVFIHSACTHR-SFHVURJKSA-N 0.000 description 1
- XVRHFURUJQNMAM-UHFFFAOYSA-N O=C(c(cc1F)ccc1F)N1CCCC1 Chemical compound O=C(c(cc1F)ccc1F)N1CCCC1 XVRHFURUJQNMAM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/44—Acylated amino or imino radicals
- C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/38—Nitrogen atoms
- C07D231/40—Acylated on said nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/08—1,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0412602.5 | 2004-06-05 | ||
| GBGB0412602.5A GB0412602D0 (en) | 2004-06-05 | 2004-06-05 | Compounds |
| GB0423041A GB0423041D0 (en) | 2004-10-16 | 2004-10-16 | Chemical compounds |
| GB0423041.3 | 2004-10-16 | ||
| GB0502961.6 | 2005-02-12 | ||
| GB0502961A GB0502961D0 (en) | 2005-02-12 | 2005-02-12 | Chemical compounds |
| PCT/GB2005/002166 WO2005121110A1 (en) | 2004-06-05 | 2005-06-01 | Hetroaryl benzamide derivatives for use as glk activators in the treatment of diabetes |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008501673A JP2008501673A (ja) | 2008-01-24 |
| JP2008501673A5 JP2008501673A5 (enExample) | 2008-08-07 |
| JP4860606B2 true JP4860606B2 (ja) | 2012-01-25 |
Family
ID=34969165
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007514127A Expired - Fee Related JP4860606B2 (ja) | 2004-06-05 | 2005-06-01 | 糖尿病の処置にｇｌｋアクチベーターとして用いるためのヘテロアリールベンズアミド誘導体 |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US7745475B2 (enExample) |
| EP (2) | EP1992623A1 (enExample) |
| JP (1) | JP4860606B2 (enExample) |
| KR (1) | KR20070024650A (enExample) |
| AR (1) | AR049139A1 (enExample) |
| AT (1) | ATE477249T1 (enExample) |
| AU (1) | AU2005251990B2 (enExample) |
| BR (1) | BRPI0511808A (enExample) |
| CA (1) | CA2566951A1 (enExample) |
| DE (1) | DE602005022859D1 (enExample) |
| ES (1) | ES2347451T3 (enExample) |
| IL (1) | IL179389A0 (enExample) |
| MX (1) | MXPA06014128A (enExample) |
| MY (1) | MY144048A (enExample) |
| NO (1) | NO20070032L (enExample) |
| NZ (1) | NZ551623A (enExample) |
| TW (1) | TW200600086A (enExample) |
| UY (1) | UY28936A1 (enExample) |
| WO (1) | WO2005121110A1 (enExample) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0102299D0 (sv) | 2001-06-26 | 2001-06-26 | Astrazeneca Ab | Compounds |
| SE0102764D0 (sv) | 2001-08-17 | 2001-08-17 | Astrazeneca Ab | Compounds |
| GB0226931D0 (en) | 2002-11-19 | 2002-12-24 | Astrazeneca Ab | Chemical compounds |
| BRPI0507746A (pt) * | 2004-02-18 | 2007-07-10 | Astrazeneca Ab | composto ou um sal, pró-droga ou solvato do mesmo, composição farmacêutica, método de tratar doenças mediadas por glk, e, processo para a preparação de um composto |
| TW200600086A (en) * | 2004-06-05 | 2006-01-01 | Astrazeneca Ab | Chemical compound |
| GB0423043D0 (en) * | 2004-10-16 | 2004-11-17 | Astrazeneca Ab | Compounds |
| GB0423044D0 (en) * | 2004-10-16 | 2004-11-17 | Astrazeneca Ab | Compounds |
| WO2006040527A1 (en) * | 2004-10-16 | 2006-04-20 | Astrazeneca Ab | Process for making phenoxy benzamide compounds |
| TW200714597A (en) * | 2005-05-27 | 2007-04-16 | Astrazeneca Ab | Chemical compounds |
| NZ564608A (en) | 2005-07-09 | 2009-09-25 | Astrazeneca Ab | Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes |
| CA2624102A1 (en) | 2005-09-29 | 2007-04-12 | Sanofi-Aventis | Phenyl- and pyridinyl- 1, 2 , 4 - oxadiazolone derivatives, processes for their preparation and their use as pharmaceuticals |
| TW200738621A (en) * | 2005-11-28 | 2007-10-16 | Astrazeneca Ab | Chemical process |
| EP2463283B1 (en) * | 2006-04-20 | 2014-06-11 | Pfizer Products Inc. | Fused phenyl Amido heterocyclic compounds for the prevention and treatment of glucokinase-mediated diseases |
| PE20080251A1 (es) | 2006-05-04 | 2008-04-25 | Boehringer Ingelheim Int | Usos de inhibidores de dpp iv |
| US7910747B2 (en) | 2006-07-06 | 2011-03-22 | Bristol-Myers Squibb Company | Phosphonate and phosphinate pyrazolylamide glucokinase activators |
| MX2009000688A (es) | 2006-07-24 | 2009-01-30 | Hoffmann La Roche | Pirazoles como activadores de glucocinasa. |
| TW200825063A (en) * | 2006-10-23 | 2008-06-16 | Astrazeneca Ab | Chemical compounds |
| SA07280576B1 (ar) * | 2006-10-26 | 2011-06-22 | استرازينيكا ايه بي | مركبات بنزويل أمينو سيكليل غير متجانسة بأعتبارها عوامل منشطة للجلوكوكيناز |
| TW200827346A (en) | 2006-11-03 | 2008-07-01 | Astrazeneca Ab | Chemical compounds |
| TW200836719A (en) | 2007-02-12 | 2008-09-16 | Astrazeneca Ab | Chemical compounds |
| CN101808995A (zh) | 2007-07-27 | 2010-08-18 | 百时美施贵宝公司 | 新颖的葡糖激酶激活剂及其使用方法 |
| WO2009022179A2 (en) * | 2007-08-14 | 2009-02-19 | Astrazeneca Ab | Glucokinase activators in the treatment of osteoarthritis |
| AR068540A1 (es) * | 2007-09-28 | 2009-11-18 | Merck & Co Inc | Metodos de produccion de un derivado de pirazol-3-il-benzamida. |
| AU2008310115B2 (en) * | 2007-10-09 | 2013-06-27 | Merck Patent Gmbh | N- ( pyrazole- 3 -yl) -benzamide derivatives as glucokinase activators |
| US7741327B2 (en) | 2008-04-16 | 2010-06-22 | Hoffmann-La Roche Inc. | Pyrrolidinone glucokinase activators |
| US8258134B2 (en) | 2008-04-16 | 2012-09-04 | Hoffmann-La Roche Inc. | Pyridazinone glucokinase activators |
| MX2011001333A (es) * | 2008-08-04 | 2011-03-15 | Astrazeneca Ab | Derivados de pirazolo [3, 4] pirimidin-4-ilo y sus usos para tratar la diabetes y obesidad. |
| GB0902406D0 (en) * | 2009-02-13 | 2009-04-01 | Astrazeneca Ab | Crystalline polymorphic form |
| GB0902434D0 (en) * | 2009-02-13 | 2009-04-01 | Astrazeneca Ab | Chemical process |
| EP2406230A1 (en) | 2009-03-11 | 2012-01-18 | Pfizer Inc. | Substituted indazole amides and their use as glucokinase activators |
| WO2010116176A1 (en) * | 2009-04-09 | 2010-10-14 | Astrazeneca Ab | Pyrazolo [4, 5-e] pyrimidine derivative and its use to treat diabetes and obesity |
| WO2010116177A1 (en) | 2009-04-09 | 2010-10-14 | Astrazeneca Ab | A pyrazolo [4,5-e] pyrimidine derivative and its use to treat diabetes and obesity |
| WO2010150280A1 (en) | 2009-06-22 | 2010-12-29 | Cadila Healthcare Limited | Disubstituted benzamide derivatives as glucokinase (gk) activators |
| MY156175A (en) | 2009-07-31 | 2016-01-15 | Cadila Healthcare Ltd | Substituted benzamide derivatives as glucokinase (gk) activators |
| KR20120120204A (ko) * | 2009-12-11 | 2012-11-01 | 아스텔라스세이야쿠 가부시키가이샤 | 벤즈아미드 화합물 |
| US8222416B2 (en) | 2009-12-14 | 2012-07-17 | Hoffmann-La Roche Inc. | Azaindole glucokinase activators |
| WO2011095997A1 (en) * | 2010-02-08 | 2011-08-11 | Advinus Therapeutics Private Limited | Benzamide compounds as glucokinase activators and their pharmaceutical application |
| US8178689B2 (en) | 2010-06-17 | 2012-05-15 | Hoffman-La Roche Inc. | Tricyclic compounds |
| WO2011158149A1 (en) | 2010-06-18 | 2011-12-22 | Pfizer Inc. | 2-(3,5-disubstitutedphenyl)pyrimidin-4(3h)-one derivatives |
| JP5792128B2 (ja) | 2011-07-29 | 2015-10-07 | 富士フイルム株式会社 | １，５−ナフチリジン誘導体又はその塩 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003015774A1 (en) * | 2001-08-17 | 2003-02-27 | Astrazeneca Ab | Compounds effecting glucokinase |
| WO2004076420A1 (ja) * | 2003-02-26 | 2004-09-10 | Banyu Pharmaceutical Co., Ltd. | ヘテロアリールカルバモイルベンゼン誘導体 |
Family Cites Families (98)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2750393A (en) | 1954-12-01 | 1956-06-12 | Sterling Drug Inc | Iodinated 5-henzamidotetrazoles and preparation thereof |
| US2967194A (en) | 1958-05-15 | 1961-01-03 | Pennsalt Chemicals Corp | 4-trifluoromethylsalicylamides |
| FR1526074A (fr) | 1967-03-22 | 1968-05-24 | Rech S Ind S O R I Soc D | Méthoxy-phényl-amino-2-thiazoles, leurs amides et leurs procédés de préparation |
| GB1352415A (en) | 1970-05-03 | 1974-05-08 | Boots Co Ltd | Esters of substituted nicotine acids |
| FR2088019A1 (en) | 1970-05-08 | 1972-01-07 | Rabot Ets David | Esters of 2 and 6-substituted nicotinic acids - with vasomotor active |
| CS173097B1 (enExample) | 1972-12-01 | 1977-02-28 | ||
| GB1400540A (en) | 1972-12-06 | 1975-07-16 | Smith Kline French Lab | Salicylamides and compositions thereof |
| US4009174A (en) | 1972-12-08 | 1977-02-22 | The Boots Company Limited | Esters of substituted nicotinic acids |
| GB1437800A (en) | 1973-08-08 | 1976-06-03 | Phavic Sprl | Derivatives of 2-benzamido-5-nitro-thiazoles |
| GB1561350A (en) | 1976-11-05 | 1980-02-20 | May & Baker Ltd | Benzamide derivatives |
| FR2344284A1 (fr) | 1976-03-17 | 1977-10-14 | Cerm Cent Europ Rech Mauvernay | Nouveaux composes tricycliques a cycle furannique et leur application comme antidepresseurs |
| GB1588242A (en) | 1977-10-28 | 1981-04-23 | May & Baker Ltd | N-(tetrazol-5-yl)-salicylamide derivatives |
| US4474792A (en) | 1979-06-18 | 1984-10-02 | Riker Laboratories, Inc. | N-Tetrazolyl benzamides and anti-allergic use thereof |
| FR2493848B2 (fr) | 1980-11-07 | 1986-05-16 | Delalande Sa | Nouveaux derives des nor-tropane et granatane, leur procede de preparation et leur application en therapeutique |
| JPS59139357A (ja) | 1983-01-28 | 1984-08-10 | Torii Yakuhin Kk | アミジン誘導体 |
| JPS62142168A (ja) | 1985-10-16 | 1987-06-25 | Mitsubishi Chem Ind Ltd | チアゾ−ル誘導体及びそれを有効成分とするロイコトリエンきつ抗剤 |
| CA1327358C (en) | 1987-11-17 | 1994-03-01 | Morio Fujiu | Fluoro cytidine derivatives |
| JP2852659B2 (ja) | 1988-03-03 | 1999-02-03 | 富山化学工業株式会社 | ピペラジン誘導体およびその塩 |
| DE3822449A1 (de) | 1988-07-02 | 1990-01-04 | Henkel Kgaa | Oxidationshaarfaerbemittel mit neuen kupplern |
| US5466715A (en) | 1991-12-31 | 1995-11-14 | Sterling Winthrop Inc. | 3,4-disubstituted phenols-immunomodulating agents |
| US5258407A (en) | 1991-12-31 | 1993-11-02 | Sterling Winthrop Inc. | 3,4-disubstituted phenols-immunomodulating agents |
| US5273986A (en) | 1992-07-02 | 1993-12-28 | Hoffmann-La Roche Inc. | Cycloalkylthiazoles |
| EP0619116A3 (en) | 1993-04-05 | 1994-11-23 | Hoechst Japan | Use of synthetic retinoids for osteopathy. |
| GB9307527D0 (en) | 1993-04-13 | 1993-06-02 | Fujisawa Pharmaceutical Co | New venzamide derivatives,processes for the preparation thereof and pharmaceutical composition comprising the same |
| US5661153A (en) | 1994-07-19 | 1997-08-26 | Japan Energy Corporation | 1-arylpyrimidine derivatives and pharmaceutical use thereof |
| US5510478A (en) | 1994-11-30 | 1996-04-23 | American Home Products Corporation | 2-arylamidothiazole derivatives with CNS activity |
| US5672750A (en) | 1994-12-16 | 1997-09-30 | Eastman Chemical Company | Preparation of aromatic amides from carbon monoxide, an amine and an aromatic chloride |
| US5849735A (en) | 1995-01-17 | 1998-12-15 | American Cyanamid Company | Tricyclic benzazepine vasopressin antagonists |
| US5712270A (en) | 1995-11-06 | 1998-01-27 | American Home Products Corporation | 2-arylamidothiazole derivatives with CNS activity |
| AUPO395396A0 (en) | 1996-12-02 | 1997-01-02 | Fujisawa Pharmaceutical Co., Ltd. | Benzamide derivatives |
| FR2757852B1 (fr) | 1996-12-31 | 1999-02-19 | Cird Galderma | Composes stilbeniques a groupement adamantyl, compositions les contenant et utilisations |
| ES2229510T3 (es) | 1997-06-27 | 2005-04-16 | Fujisawa Pharmaceutical Co., Ltd. | Derivados de anillo aromatico. |
| RU2199532C2 (ru) | 1997-06-27 | 2003-02-27 | Фудзисава Фармасьютикал Ко., Лтд. | Сульфонамидное соединение |
| US6613942B1 (en) | 1997-07-01 | 2003-09-02 | Novo Nordisk A/S | Glucagon antagonists/inverse agonists |
| US6114483A (en) | 1997-08-27 | 2000-09-05 | E. I. Du Pont De Nemours And Company | Polymerization of olefins |
| JP4398585B2 (ja) | 1997-11-12 | 2010-01-13 | 有限会社ケムフィズ | レチノイドレセプター作用剤 |
| GB9725298D0 (en) | 1997-11-28 | 1998-01-28 | Zeneca Ltd | Insecticidal thiazole derivatives |
| WO1999038845A1 (en) | 1998-01-29 | 1999-08-05 | Tularik Inc. | Ppar-gamma modulators |
| DE19816780A1 (de) | 1998-04-16 | 1999-10-21 | Bayer Ag | Substituierte 2-Oxo-alkansäure-[2-(indol-3-yl)-ethyl]amide |
| GB9811969D0 (en) | 1998-06-03 | 1998-07-29 | Celltech Therapeutics Ltd | Chemical compounds |
| US6197798B1 (en) | 1998-07-21 | 2001-03-06 | Novartis Ag | Amino-benzocycloalkane derivatives |
| JP4191825B2 (ja) | 1998-09-10 | 2008-12-03 | あすか製薬株式会社 | ５−アミノイソキサゾール誘導体 |
| RU2242469C2 (ru) | 1999-03-29 | 2004-12-20 | Ф.Хоффманн-Ля Рош Аг | Активаторы глюкокиназы |
| CZ301366B6 (cs) | 1999-03-29 | 2010-02-03 | F. Hoffmann-La Roche Ag | 2-Fenyl-3-cykloalkylpropionamidová sloucenina, zpusob její prípravy a farmaceutický prostredek s jejím obsahem |
| US6610846B1 (en) | 1999-03-29 | 2003-08-26 | Hoffman-La Roche Inc. | Heteroaromatic glucokinase activators |
| US6320050B1 (en) | 1999-03-29 | 2001-11-20 | Hoffmann-La Roche Inc. | Heteroaromatic glucokinase activators |
| WO2001035950A2 (en) | 1999-11-18 | 2001-05-25 | Centaur Pharmaceuticals, Inc. | Benzamide therapeutics and methods for treating inflammatory bowel disease |
| US6353111B1 (en) | 1999-12-15 | 2002-03-05 | Hoffmann-La Roche Inc. | Trans olefinic glucokinase activators |
| ES2254385T3 (es) | 2000-02-29 | 2006-06-16 | Millennium Pharmaceuticals, Inc. | Benzamidas e inhibidores relacionados del factor xa. |
| EP1132381A1 (en) | 2000-03-08 | 2001-09-12 | Cermol S.A. | Ester derivatives of dimethylpropionic acid and pharmaceutical compositions containing them |
| US6534651B2 (en) | 2000-04-06 | 2003-03-18 | Inotek Pharmaceuticals Corp. | 7-Substituted isoindolinone inhibitors of inflammation and reperfusion injury and methods of use thereof |
| CA2407416C (en) | 2000-05-03 | 2006-07-18 | Paige Erin Mahaney | Alkynyl phenyl heteroaromatic glucokinase activators |
| EA011309B1 (ru) * | 2000-06-13 | 2009-02-27 | Вайет | Составы для ослабления боли, содержащие целекоксиб |
| RU2276137C2 (ru) | 2000-11-22 | 2006-05-10 | Астеллас Фарма Инк. | Замещенные производные бензола или их соли, фармацевтическая композиция на их основе |
| WO2002046173A1 (en) | 2000-12-06 | 2002-06-13 | F. Hoffmann-La Roche Ag | Fused heteroaromatic glucokinase activators |
| US7132546B2 (en) | 2000-12-22 | 2006-11-07 | Ishihara Sangyo Kaisha, Ltd. | Aniline derivatives or salts thereof and cytokine production inhibitors containing the same |
| US20040077697A1 (en) | 2001-02-02 | 2004-04-22 | Hiroyuki Koshio | 2-Acylaminothiazole derivative or its salt |
| SE0102299D0 (sv) | 2001-06-26 | 2001-06-26 | Astrazeneca Ab | Compounds |
| SE0102300D0 (sv) | 2001-06-26 | 2001-06-26 | Astrazeneca Ab | Compounds |
| NZ531153A (en) | 2001-08-09 | 2005-10-28 | Ono Pharmaceutical Co | Carboxylic acid derivative compounds and drugs comprising these compounds as the active ingredient |
| EP1336607A1 (en) | 2002-02-19 | 2003-08-20 | Novo Nordisk A/S | Amide derivatives as glucokinase activators |
| DE10161765A1 (de) | 2001-12-15 | 2003-07-03 | Bayer Cropscience Gmbh | Substituierte Phenylderivate |
| US6911545B2 (en) | 2001-12-19 | 2005-06-28 | Hoffman-La Roche Inc. | Crystals of glucokinase and methods of growing them |
| WO2003055482A1 (en) | 2001-12-21 | 2003-07-10 | Novo Nordisk A/S | Amide derivatives as gk activators |
| WO2003080585A1 (en) | 2002-03-26 | 2003-10-02 | Banyu Pharmaceutical Co., Ltd. | Novel aminobenzamide derivative |
| DE60309856T2 (de) | 2002-04-26 | 2007-06-14 | F. Hoffmann-La Roche Ag | Substituierte phenylacetamide und deren verwendung als glucokinaseaktivatoren |
| AU2003243921B2 (en) | 2002-06-27 | 2009-05-07 | Novo Nordisk A/S | Aryl carbonyl derivatives as therapeutic agents |
| AU2003252478A1 (en) | 2002-07-10 | 2004-02-02 | Ono Pharmaceutical Co., Ltd. | Ccr4 antagonist and medicinal use thereof |
| GB0226930D0 (en) | 2002-11-19 | 2002-12-24 | Astrazeneca Ab | Chemical compounds |
| GB0226931D0 (en) | 2002-11-19 | 2002-12-24 | Astrazeneca Ab | Chemical compounds |
| WO2004080966A1 (ja) | 2003-03-14 | 2004-09-23 | Ono Pharmaceutical Co., Ltd. | 含窒素複素環誘導体およびそれらを有効成分とする薬剤 |
| US20050267182A1 (en) | 2003-11-13 | 2005-12-01 | Ambit Biosciences Corporation | Urea derivatives as FLT-3 modulators |
| GB0327760D0 (en) | 2003-11-29 | 2003-12-31 | Astrazeneca Ab | Compounds |
| GB0327761D0 (en) | 2003-11-29 | 2003-12-31 | Astrazeneca Ab | Compounds |
| GB0328178D0 (en) | 2003-12-05 | 2004-01-07 | Astrazeneca Ab | Compounds |
| US7728025B2 (en) | 2003-12-29 | 2010-06-01 | Banyu Pharmaceutical Co., Ltd. | 2-heteroaryl-substituted benzimidazole derivative |
| CA2554686A1 (en) | 2004-02-18 | 2005-09-01 | Astrazeneca Ab | Compounds |
| BRPI0507746A (pt) | 2004-02-18 | 2007-07-10 | Astrazeneca Ab | composto ou um sal, pró-droga ou solvato do mesmo, composição farmacêutica, método de tratar doenças mediadas por glk, e, processo para a preparação de um composto |
| TW200600086A (en) | 2004-06-05 | 2006-01-01 | Astrazeneca Ab | Chemical compound |
| NZ553696A (en) | 2004-09-13 | 2010-02-26 | Ono Pharmaceutical Co | Nitrogenous heterocyclic derivative and medicine containing the same as an active ingredient |
| GB0423043D0 (en) | 2004-10-16 | 2004-11-17 | Astrazeneca Ab | Compounds |
| WO2006040527A1 (en) | 2004-10-16 | 2006-04-20 | Astrazeneca Ab | Process for making phenoxy benzamide compounds |
| GB0423044D0 (en) | 2004-10-16 | 2004-11-17 | Astrazeneca Ab | Compounds |
| AU2006239632B2 (en) | 2005-04-25 | 2012-03-15 | Merck Patent Gmbh | Novel AZA- heterocycles serving as kinase inhibitors |
| TW200714597A (en) | 2005-05-27 | 2007-04-16 | Astrazeneca Ab | Chemical compounds |
| EP2027113A1 (en) | 2005-07-09 | 2009-02-25 | AstraZeneca AB | Heteroaryl benzamide derivatives for use as glk activators in the treatment of diabetes |
| NZ564608A (en) | 2005-07-09 | 2009-09-25 | Astrazeneca Ab | Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes |
| JP2009508832A (ja) | 2005-09-16 | 2009-03-05 | アストラゼネカ アクチボラグ | グルコキナーゼ活性化剤としてのヘテロ二環式化合物 |
| TW200738621A (en) | 2005-11-28 | 2007-10-16 | Astrazeneca Ab | Chemical process |
| WO2007105637A1 (ja) | 2006-03-10 | 2007-09-20 | Ono Pharmaceutical Co., Ltd. | 含窒素複素環誘導体およびそれらを有効成分とする薬剤 |
| TW200825063A (en) | 2006-10-23 | 2008-06-16 | Astrazeneca Ab | Chemical compounds |
| SA07280576B1 (ar) | 2006-10-26 | 2011-06-22 | استرازينيكا ايه بي | مركبات بنزويل أمينو سيكليل غير متجانسة بأعتبارها عوامل منشطة للجلوكوكيناز |
| BRPI0721143A2 (pt) | 2006-12-21 | 2014-03-11 | Astrazeneca Ab | Forma cristalina do composto processo para a formação da mesma, uso de um composto, método para tratar doenças mediadas por ativador de glicocinase |
| MX2011001333A (es) * | 2008-08-04 | 2011-03-15 | Astrazeneca Ab | Derivados de pirazolo [3, 4] pirimidin-4-ilo y sus usos para tratar la diabetes y obesidad. |
| GB0902434D0 (en) * | 2009-02-13 | 2009-04-01 | Astrazeneca Ab | Chemical process |
| GB0902406D0 (en) * | 2009-02-13 | 2009-04-01 | Astrazeneca Ab | Crystalline polymorphic form |
| WO2010116177A1 (en) * | 2009-04-09 | 2010-10-14 | Astrazeneca Ab | A pyrazolo [4,5-e] pyrimidine derivative and its use to treat diabetes and obesity |
| WO2010116176A1 (en) * | 2009-04-09 | 2010-10-14 | Astrazeneca Ab | Pyrazolo [4, 5-e] pyrimidine derivative and its use to treat diabetes and obesity |
-
2005
- 2005-05-25 TW TW094117058A patent/TW200600086A/zh unknown
- 2005-06-01 US US11/628,448 patent/US7745475B2/en not_active Expired - Fee Related
- 2005-06-01 MX MXPA06014128A patent/MXPA06014128A/es active IP Right Grant
- 2005-06-01 KR KR1020067027324A patent/KR20070024650A/ko not_active Ceased
- 2005-06-01 JP JP2007514127A patent/JP4860606B2/ja not_active Expired - Fee Related
- 2005-06-01 EP EP08154684A patent/EP1992623A1/en not_active Withdrawn
- 2005-06-01 AT AT05747241T patent/ATE477249T1/de not_active IP Right Cessation
- 2005-06-01 BR BRPI0511808-5A patent/BRPI0511808A/pt not_active IP Right Cessation
- 2005-06-01 DE DE602005022859T patent/DE602005022859D1/de not_active Expired - Lifetime
- 2005-06-01 WO PCT/GB2005/002166 patent/WO2005121110A1/en not_active Ceased
- 2005-06-01 CA CA002566951A patent/CA2566951A1/en not_active Abandoned
- 2005-06-01 AU AU2005251990A patent/AU2005251990B2/en not_active Ceased
- 2005-06-01 EP EP05747241A patent/EP1756076B1/en not_active Expired - Lifetime
- 2005-06-01 NZ NZ551623A patent/NZ551623A/en unknown
- 2005-06-01 ES ES05747241T patent/ES2347451T3/es not_active Expired - Lifetime
- 2005-06-02 MY MYPI20052532A patent/MY144048A/en unknown
- 2005-06-02 AR ARP050102265A patent/AR049139A1/es not_active Application Discontinuation
- 2005-06-02 UY UY28936A patent/UY28936A1/es not_active Application Discontinuation
-
2006
- 2006-11-19 IL IL179389A patent/IL179389A0/en unknown
-
2007
- 2007-01-03 NO NO20070032A patent/NO20070032L/no not_active Application Discontinuation
-
2008
- 2008-12-16 US US12/336,170 patent/US20090253676A1/en not_active Abandoned
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003015774A1 (en) * | 2001-08-17 | 2003-02-27 | Astrazeneca Ab | Compounds effecting glucokinase |
| WO2004076420A1 (ja) * | 2003-02-26 | 2004-09-10 | Banyu Pharmaceutical Co., Ltd. | ヘテロアリールカルバモイルベンゼン誘導体 |
Also Published As
| Publication number | Publication date |
|---|---|
| BRPI0511808A (pt) | 2008-01-15 |
| TW200600086A (en) | 2006-01-01 |
| US20090253676A1 (en) | 2009-10-08 |
| NO20070032L (no) | 2007-02-27 |
| IL179389A0 (en) | 2007-03-08 |
| HK1102091A1 (en) | 2007-11-02 |
| ATE477249T1 (de) | 2010-08-15 |
| AR049139A1 (es) | 2006-06-28 |
| MXPA06014128A (es) | 2007-01-31 |
| WO2005121110A1 (en) | 2005-12-22 |
| MY144048A (en) | 2011-07-29 |
| AU2005251990B2 (en) | 2008-11-20 |
| UY28936A1 (es) | 2006-01-31 |
| US20080015203A1 (en) | 2008-01-17 |
| DE602005022859D1 (de) | 2010-09-23 |
| ES2347451T3 (es) | 2010-10-29 |
| KR20070024650A (ko) | 2007-03-02 |
| US7745475B2 (en) | 2010-06-29 |
| AU2005251990A1 (en) | 2005-12-22 |
| JP2008501673A (ja) | 2008-01-24 |
| CA2566951A1 (en) | 2005-12-22 |
| EP1756076B1 (en) | 2010-08-11 |
| EP1992623A1 (en) | 2008-11-19 |
| EP1756076A1 (en) | 2007-02-28 |
| NZ551623A (en) | 2009-11-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7745475B2 (en) | Heteroaryl benzamide derivatives as GLK activators | |
| EP1718624B1 (en) | Benzamide derivatives and their use as glucokinase activating agents | |
| JP4673429B2 (ja) | グルコキナーゼ（ｇｌｋ）活性化剤としてのベンゾイルアミノヘテロシクリル化合物 | |
| US20080312207A1 (en) | Compounds | |
| JP2009504621A (ja) | 糖尿病の処置のためのヘテロアリールカルバモイルベンゼン誘導体 | |
| US20080234273A1 (en) | Heteroaryl Benzamide Derivatives for Use as Glk Activators in the Treatment of Diabetes | |
| JP2008516936A (ja) | ２型糖尿病および肥満の処置において有用であるフェノキシベンズアミド化合物 | |
| CN101072757A (zh) | 苯甲酰胺衍生物对葡萄糖激酶酶的作用 | |
| CN101018773A (zh) | 在糖尿病治疗中用作glk激活剂的杂芳基苯甲酰胺衍生物 | |
| CN101218230A (zh) | 在糖尿病治疗中用作glk激活剂的杂芳基苯甲酰胺衍生物 | |
| HK1125102A (en) | Heteroaryl benzamide derivative for use as glk activator in the treatment of diabetes | |
| HK1096092B (en) | Benzamide derivatives and their use as glucokinase activating agents | |
| HK1129222A (en) | Benzamide derivatives and their use as glucokinase activating agents | |
| MXPA06009511A (en) | Benzamide derivatives and their use as glucokinae activating agents |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080602 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20080602 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110419 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20110420 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20110706 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20110713 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20110803 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110901 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20111005 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20111102 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20141111 Year of fee payment: 3 |
|
| LAPS | Cancellation because of no payment of annual fees |